AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.
A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients.
Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.
Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.
Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.
German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.
Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.
Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.